Anti‐CD70 treatment and combined therapy with immune checkpoint inhibitors may thus have potential for EBV+ DLBCL and possibly also other EBV‐associated, CD70‐expressing malignancies. This evidence concerns the gene CD70 and diffuse large B-cell lymphoma.